Published in J Clin Oncol on January 01, 1994
Cancer Immune Therapy for the Treatment of Refractory Solid Tumours of Childhood | NCT02533895
Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood (2011) 3.82
Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study. J Clin Oncol (2010) 1.57
Promising therapeutic targets in neuroblastoma. Clin Cancer Res (2012) 1.48
Anti-GD2 antibody therapy for GD2-expressing tumors. Curr Cancer Drug Targets (2010) 1.28
Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells. Clin Cancer Res (2009) 1.15
Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy. BMC Cancer (2011) 1.13
Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma. J Clin Oncol (2014) 1.09
Immunology and immunotherapy of neuroblastoma. Semin Cancer Biol (2011) 1.08
Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma. Cancer (2013) 1.02
Anti-GD2 Strategy in the Treatment of Neuroblastoma. Drugs Future (2010) 1.00
The inducible caspase-9 suicide gene system as a "safety switch" to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. Front Pharmacol (2014) 0.95
Anti-Gb3 monoclonal antibody inhibits angiogenesis and tumor development. PLoS One (2012) 0.94
The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma. Expert Opin Investig Drugs (2009) 0.92
A monoclonal antibody to O-acetyl-GD2 ganglioside and not to GD2 shows potent anti-tumor activity without peripheral nervous system cross-reactivity. PLoS One (2011) 0.91
Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: a phase I study. J Clin Oncol (2011) 0.90
GD2-targeted immunotherapy and radioimmunotherapy. Semin Oncol (2014) 0.86
Immune therapies for neuroblastoma. Cancer Biol Ther (2009) 0.85
New aspects of neuroblastoma treatment: ASPHO 2011 symposium review. Pediatr Blood Cancer (2012) 0.82
Enhancing Cancer Immunotherapy Via Activation of Innate Immunity. Semin Oncol (2015) 0.79
Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy. Immunotherapy (2016) 0.77
Posterior reversible encephalopathy syndrome in neuroblastoma patients receiving anti-GD2 3F8 monoclonal antibody. Cancer (2013) 0.77
Comparison of pain outcomes between two anti-GD2 antibodies in patients with neuroblastoma. Pediatr Blood Cancer (2014) 0.76
Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet (2001) 2.85
Extraskeletal osteosarcoma. A clinicopathologic review of 26 cases. Cancer (1990) 2.56
Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol (1997) 2.32
Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med (1997) 2.22
Adriamycin chemotherapy--efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule. Cancer (1974) 2.10
Alveolar soft part sarcoma: clinical course and patterns of metastasis in 70 patients treated at a single institution. Cancer (2001) 1.89
Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med (1982) 1.85
Germline p53 gene mutations in subsets of glioma patients. J Natl Cancer Inst (1994) 1.81
An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol (2012) 1.81
Diagnosing pulmonary embolism. Chest (1995) 1.77
Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res (1987) 1.68
The prevalence of high-level exercise in the eating disorders: etiological implications. Compr Psychiatry (1998) 1.67
Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer (1995) 1.65
Evaluation of prostAsure index in the detection of prostate cancer: a preliminary report. Urology (1998) 1.64
Preoperative chemotherapy for soft-tissue sarcomas of the extremities. Ann Surg (1990) 1.59
Ki-67 immunostaining in node-negative stage I/II breast carcinoma. Significant correlation with prognosis. Cancer (1991) 1.57
Improved conjugate view quantitation of I-131 by subtraction of scatter and septal penetration events with a triple energy window method. Med Phys (1995) 1.56
Soft tissue sarcomas of the head and neck in adolescents and adults. Am J Surg (1986) 1.50
Clinical pharmacology, metabolism, and tissue distribution of 90Y-labeled monoclonal antibody B72.3 after intraperitoneal administration. J Natl Cancer Inst (1991) 1.49
Prostate-specific antigen and prostate gland volume: correlation and clinical application. J Clin Lab Anal (1990) 1.48
Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol (2001) 1.47
Adriamycin cardiomyopathy--risk factors. Cancer (1977) 1.46
Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol (1998) 1.45
Role of DTIC (NSC-45388) in the chemotherapy of sarcomas. Cancer Treat Rep (1976) 1.45
Long-term outcome of patients with American Joint Committee on Cancer stage IIB extremity soft tissue sarcomas. J Clin Oncol (1999) 1.45
Survival of patients with multiple primary malignancies: a study of 783 patients with gastrointestinal stromal tumor. Ann Oncol (2010) 1.42
Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins. J Cell Biol (1986) 1.42
Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. J Natl Cancer Inst (1991) 1.40
Variables influencing tumor uptake of anti-melanoma monoclonal antibodies radioiodinated using para-iodobenzoyl (PIB) conjugate. J Nucl Med (1991) 1.39
Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veridex CellSearch™ system. Int J Cancer (2011) 1.38
Avicins: triterpenoid saponins from Acacia victoriae (Bentham) induce apoptosis by mitochondrial perturbation. Proc Natl Acad Sci U S A (2001) 1.37
Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases. J Nucl Med (1994) 1.37
BioCARS: a synchrotron resource for time-resolved X-ray science. J Synchrotron Radiat (2011) 1.37
Combination chemotherapy in adult desmoid tumors. Cancer (1993) 1.36
Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function. Cancer Res (1977) 1.36
High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence. J Clin Oncol (1997) 1.34
Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors. J Clin Oncol (2000) 1.34
Patterns of recurrence in extremity liposarcoma: implications for staging and follow-up. Cancer (1999) 1.31
Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol (1998) 1.29
Role of radiotherapy in sarcoma of the breast--a retrospective review of the M.D. Anderson experience. Radiother Oncol (1999) 1.29
A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin. J Clin Oncol (1984) 1.28
Sarcoma of the breast: implications for extent of therapy. The M. D. Anderson experience. Surgery (1994) 1.28
Doxorubicin-induced congestive heart failure in adults. Cancer (1985) 1.26
Technical validation of an autoantibody test for lung cancer. Ann Oncol (2010) 1.25
Cardiotoxicity in patients receiving transtuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifact? Semin Oncol (1999) 1.25
Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer (1993) 1.25
Of mice and men: divergent risks of teriparatide-induced osteosarcoma. Osteoporos Int (2009) 1.22
Chemotherapy for metastatic carcinoid tumors: experiences with 32 patients and a review of the literature. Cancer Treat Rep (1977) 1.21
Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge. JAMA (1988) 1.20
Pharmacokinetics and metabolism of adriamycin in man. Clin Pharmacol Ther (1973) 1.19
Randomized placebo-controlled trial of isotretinoin in chemoprevention of bronchial squamous metaplasia. J Clin Oncol (1994) 1.18
Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. J Urol (1998) 1.18
Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. J Clin Oncol (2001) 1.17
Extraskeletal myxoid chondrosarcoma. Long-term experience with chemotherapy. Am J Clin Oncol (1995) 1.15
Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Crit Rev Oncol Hematol (2001) 1.14
CA 125 in ovarian cancer: advances and controversy. Clin Chem (1998) 1.14
A modified agarose method for detection of migration inhibitory factor and delineation of its antigen dependency. Int Arch Allergy Appl Immunol (1973) 1.14
Myxoid liposarcoma. Experience with chemotherapy. Cancer (1994) 1.13
Dedifferentiated chordoma. Response to aggressive chemotherapy in two cases. Cancer (1993) 1.09
Arterial occlusion: management of giant cell tumor and aneurysmal bone cyst. AJR Am J Roentgenol (1981) 1.09
Obsessive compulsiveness and physical activity in anorexia nervosa and high-level exercising. J Psychosom Res (1995) 1.07
Prevalence of hypertension: a screening survey in an adult population. Can J Public Health (1980) 1.05
Conventional and dedifferentiated parosteal osteosarcoma. Diagnosis, treatment, and outcome. Cancer (1996) 1.05
Behavioral frequency and psychological commitment: necessary concepts in the study of excessive exercising. J Behav Med (1993) 1.04
Preoperative chemotherapy for stage IIIB extremity soft tissue sarcoma: long-term results from a single institution. J Clin Oncol (1997) 1.04
Malignant melanoma of soft parts (clear cell sarcoma). A study of 17 cases, with emphasis on prognostic factors. Cancer (1990) 1.03
In vivo and in vitro measurement of apoptosis in breast cancer cells using 99mTc-EC-annexin V. Cancer Biother Radiopharm (2001) 1.03
Utility of chest computed tomography for staging in patients with T1 extremity soft tissue sarcomas. Cancer (2001) 1.02
Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease. J Clin Oncol (1997) 1.01
Pilot study of vitaxin--an angiogenesis inhibitor-in patients with advanced leiomyosarcomas. Cancer (2001) 1.01
Epithelioid sarcoma: results of conservative surgery and radiotherapy. Int J Radiat Oncol Biol Phys (2001) 1.01
N-(4-hydroxyphenyl)retinamide in the chemoprevention of squamous metaplasia and dysplasia of the bronchial epithelium. Clin Cancer Res (2000) 1.00
Human tissue distribution of platinum after cis-diamminedichloroplatinum. Cancer Chemother Pharmacol (1982) 1.00
Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia. J Clin Oncol (1995) 1.00
Lymphocytotoxins and pernicious anemia. Blood (1972) 0.99
Assessment of anthracycline cardiomyopathy by endomyocardial biopsy. Ultrastruct Pathol (1994) 0.99
Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration. J Clin Oncol (1992) 0.99
Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia. Radiology (1995) 0.99
Alterations of p53, cyclin D1, Rb, and H-ras in human oral carcinomas related to tobacco use. Cancer (1998) 0.98
Phase II study with sequential L-asparaginase and methotrexate in advanced refractory breast cancer. Cancer Treat Rep (1979) 0.98
Response to chemotherapy does not predict survival after resection of sarcomatous pulmonary metastases. Ann Thorac Surg (1991) 0.98
Comparison of immunocytochemical and biochemical assays for estrogen receptor in fine needle aspirates and histologic sections from breast carcinomas. Breast Cancer Res Treat (1990) 0.98
Ectopic production of the beta-subunit of human chorionic gonadotropin in osteosarcoma. Arch Pathol Lab Med (1989) 0.98
Activation of tumoricidal properties in monocytes from cancer patients following intravenous administration of liposomes containing muramyl tripeptide phosphatidylethanolamine. Cancer Res (1989) 0.97
Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma. Am J Clin Oncol (1995) 0.97
Sarcoma of the stomach: clinicopathologic study of 43 cases. J Surg Oncol (1980) 0.97
Primary extraskeletal osteosarcoma--experience with chemotherapy. J Natl Cancer Inst (1995) 0.97
A phase II trial of taxol in metastatic melanoma. Cancer (1990) 0.97
Impact of neoadjuvant chemotherapy on postoperative morbidity in soft tissue sarcomas. J Clin Oncol (2000) 0.96
A 15-year experience with chemotherapy of patients with paraganglioma. Cancer (1995) 0.96
The natural history of resectable metastatic melanoma (Stage IVA melanoma). Cancer (1982) 0.96
Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients. J Clin Oncol (1989) 0.96
Serial plasma carcinoembryonic antigen measurements during treatment of metastatic breast cancer. JAMA (1983) 0.95
A human brain glycoprotein related to the mouse cell adhesion molecule L1. J Biol Chem (1988) 0.95
Clinical pharmacology of intraarterial cis-diamminedichloroplatinum(II). Cancer Res (1983) 0.95
Primary soft tissue sarcoma of the breast. Curr Treat Options Oncol (2001) 0.95
The natural history of metastatic synovial sarcoma: experience of the Southwest Oncology group. Clin Orthop Relat Res (1982) 0.94
Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer. J Nucl Med (1996) 0.94
Phase I study of tricyclic nucleoside phosphate using a five-day continuous infusion schedule. Cancer Res (1984) 0.94